Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy

The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.

Inclusion Criteria:

• Patient has Type 2 diabetes
• Currently taking metformin >1500 mg/day for at least 10 weeks
• Male or female

Exclusion Criteria:

• Patient has peripheral edema
• History of type 1 diabetes
• Patient required insulin within prior 8 weeks
• Have participated or are currently participating in another study with an investigational compound or device within 12 weeks of starting this study
• Participating in a weight loss program